P00520 (ABL1_MOUSE) Mus musculus (Mouse)
Tyrosine-protein kinase ABL1 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
24 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
CRYSTAL STRUCTURE OF THE COMPLEX OF THE ABL TYROSINE KINASE SH3 DOMAIN WITH 3BP-1 SYNTHETIC PEPTIDE |
Heteromer P55194; | 1×SO4; | ||||
Assess | ||||||
Structure, thermodynamics, and the role of conformational dynamics in the interactions between the … |
Heteromer Q64010; | 1×PEG; 3×NA; | ||||
Assess | ||||||
CRYSTAL STRUCTURE OF THE UNLIGANDED ABL TYROSINE KINASE SH3 DOMAIN | homo-2-mer | |||||
Assess | ||||||
Structural basis for the auto-inhibition of c-Abl tyrosine kinase | monomer | 1×MYR; 1×P16; 1×GOL; | ||||
Assess | ||||||
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine tem… | monomer | 1×B90; | ||||
Assess | ||||||
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant a… | monomer | 1×0LI; | ||||
Assess | ||||||
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine tem… | monomer | 1×B91; | ||||
Assess | ||||||
Crystal Structure of the T315I Mutant of Abl kinase bound with PPY-A | monomer | 1×P3Y; | ||||
Assess | ||||||
Crystal structure of ABL T315I mutant kinase domain bound with a DFG-out inhibitor AP24589 | monomer | 1×XY3; | ||||
Assess | ||||||
Crystal structure of ABL kinase domain bound with a DFG-out inhibitor AP24534 | monomer | 1×0LI; | ||||
Assess | ||||||
Structure of Abl kinase in complex with imatinib and GNF-2 | monomer | 1×STJ; 1×STI; 1×CL; | ||||
Assess | ||||||
Structural basis for the auto-inhibition of c-Abl tyrosine kinase | monomer | 1×CL; 1×MYR; 1×STI; | ||||
Assess | ||||||
ABL1 IN COMPLEX WITH COMPOUND 7 AND IMATINIB (STI-571) | monomer | 1×GOL; 1×CL; 1×FYW; 1×STI; | ||||
Assess | ||||||
ABL1 IN COMPLEX WITH COMPOUND6 AND IMATINIB (STI-571) | monomer | 1×CL; 1×FYH; 1×STI; | ||||
Assess | ||||||
Abl kinase domain in complex with NVP-AFG210 | monomer | 1×KIN; | ||||
Assess | ||||||
Crystal Structure of Abl kinase bound with PPY-A | monomer | 1×P3Y; | ||||
Assess | ||||||
CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR | monomer | 1×PRC; | ||||
Assess | ||||||
Crystal Structure of the c-Abl Kinase domain in complex with PD173955 | monomer | 1×P17; | ||||
Assess | ||||||
Crystal structure of mutant ABL kinase domain in complex with small molecule fragment | monomer | 1×SX7; | ||||
Assess | ||||||
Crystal structure of mutant ABL kinase domain in complex with small molecule fragment | monomer | 1×SX7; | ||||
Assess | ||||||
Crystal structure of mutant ABL kinase domain in complex with small molecule fragment | monomer | 1×SX7; | ||||
Assess | ||||||
CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571. | monomer | 4×CL; 1×STI; | ||||
Assess | ||||||
ABL kinase in complex with imatinib and a fragment (FRAG1) in the myristate pocket | monomer | 1×STI; 1×MS9; 4×CL; | ||||
Assess | ||||||
Abl kinase in complex with imatinib and fragment (FRAG2) in the myristate site | monomer | 1×STI; 1×MS7; | ||||
Assess |
4 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
1opk.1.A | monomer | 0.80 | 1×MYR; 1×P16; | 99.80 | ||
Assess | ||||||
1opl.2.A | monomer | 0.78 | 1×P16; | 98.97 | ||
Assess | ||||||
1zzp.1.A | monomer | 0.78 | 95.97 | |||
Assess | ||||||
1y57.1.A | monomer | 0.71 | 43.39 | |||
Assess |
12 SWISS-MODEL models built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
---|---|---|---|---|---|---|
Isoform 2 | 1opk.1.A | monomer | 0.80 | 1×MYR; 1×P16; | 99.79 | |
Assess | ||||||
Isoform 2 | 1opl.2.A | monomer | 0.78 | 1×P16; | 98.57 | |
Assess | ||||||
Isoform 2 | 1zzp.1.A | monomer | 0.78 | 95.97 | ||
Assess | ||||||
Isoform 2 | 1y57.1.A | monomer | 0.71 | 43.39 | ||
Assess | ||||||
Isoform 3 | 1opk.1.A | monomer | 0.81 | 1×MYR; 1×P16; | 99.80 | |
Assess | ||||||
Isoform 3 | 1opl.2.A | monomer | 0.79 | 1×P16; | 98.77 | |
Assess | ||||||
Isoform 3 | 1zzp.1.A | monomer | 0.78 | 95.97 | ||
Assess | ||||||
Isoform 3 | 1y57.1.A | monomer | 0.71 | 43.39 | ||
Assess | ||||||
Isoform 4 | 1opl.1.A | monomer | 0.81 | 1×MYR; 1×P16; | 99.44 | |
Assess | ||||||
Isoform 4 | 1opl.2.A | monomer | 0.79 | 1×P16; | 99.43 | |
Assess | ||||||
Isoform 4 | 1zzp.1.A | monomer | 0.78 | 95.97 | ||
Assess | ||||||
Isoform 4 | 1y57.1.A | monomer | 0.71 | 43.39 | ||
Assess |